Fédération Francophone de Cancérologie Digestive

Recent papers from Fédération Francophone de Cancérologie Digestive

1. Cancer Patients Mortality From Other Causes: A European Population‐Based StudyCancer Medicine · 2026
2. Usability and relevance of specialized population-based cancer registry data in externally controlled trialsJournal of Clinical Epidemiology · 2026
3. Predicting severe toxicities and mortality in older patients with colorectal cancer: An analysis of 3 clinical trials and 3 prospective cohorts.European Journal of Cancer · 2026
4. Impact of postoperative chemotherapy in patients resected for esophagogastric adenocarcinoma with major pathological response after preoperative chemotherapy: a study from the FREGAT databaseTherapeutic Advances in Medical Oncology · 2026
5. Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapyJournal for ImmunoTherapy of Cancer · 2026
6. Small extracellular vesicle-mediated transfer of HPV16 transcripts from Ca Ski cells increases proliferation of HPV-negative recipient cancer cellsCell Communication and Signaling · 2026
7. Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France)EClinicalMedicine · 2026
8. FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinomaDigestive and Liver Disease · 2026
9. Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohortsOncoImmunology · 2026
10. Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trial.2026
11. Early-Onset Metastatic Colorectal Adenocarcinoma Incidence and Survival Among Patients Younger Than 50 YearsJAMA Network Open · 2026
12. Enhanced Recovery After Liver Surgery: Does Compliance Impact Survival?Annals of Surgical Oncology · 2026
13. Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus – An ancillary study of the FFCD0904 phase I and II trialBiomedicine & Pharmacotherapy · 2026
14. 371P System dynamics analysis of access pathways and hurdles for ctDNA-based MRD testing in solid tumorsESMO Open · 2026
15. Ability of computed tomography and endoscopic ultrasound to predict pTNM of resected ampullary adenocarcinomas (AC): an analysis of the French Fédération Française de Cancérologie Digestive AC prospective cohort studyGastrointestinal Endoscopy · 2026
16. Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinomaDigestive and Liver Disease · 2026
17. A randomized phase III trial of structured tumour response surveillance and shared decision‐making for organ preservation in rectal cancer – PRODIGE 101‐ GRECCAR 20‐ EVAREC trial protocolColorectal Disease · 2026
18. Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancerSHILAP Revista de lepidopterología · 2025
19. Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV : Results from the ANRS CO4 French hospital database on HIVInternational Journal of Cancer · 2025
20. Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV : Results from the ANRS CO4 French hospital database on HIVInternational Journal of Cancer · 2025